Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Holding(s) in Company

19th Apr 2011 14:00

Notification of major interests in shares

April 19, 2011 - Shire plc

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc 2. Reason for the notification State Yes/No An acquisition or disposal of voting rights Yes

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An event changing the breakdown of voting rights Other (please specify):

3. Full name of person(s) subject to the notification obligation: FMR LLC

4. Full name of shareholder(s) (if different from 3.):

5. Date of the transaction (and date on which the threshold is 14 April crossed

2011 or reached if different): 6. Date on which issuer notified: 18 April 2011 7. Threshold(s) that is/are crossed or reached: 5% 8. Notified details:

A: Voting rights attached to shares

Situation previous to Resulting situation after the triggering the Triggering transaction transaction Class/type of shares Number Number Number Number of voting % of voting if possible of of of rights rights using the Shares Voting shares ISIN CODE Rights Direct Indirect Direct Indirect Direct Indirect JE00B2QKY057 27,810,001 27,810,001 28,129,636 28,129,636 5% B: Financial Instruments

Resulting situation after the triggering transaction

Type of Expiration Exercise/ Number of voting % of financial date Conversion rights that may be voting instrument Period/ Date acquired if the rights instrument is exercised/converted n/a Total (A+B)

Number of voting rights % of voting rights

28,129,636 5%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

FMR LLC is the parent holding company of Fidelity Management & Research Company (FMRCO), investment manager for US mutual funds, FIL Management Trust Company (FMTC),

Pyramis Global Advisors Trust Company (PGATC), a US state chartered bank which acts as a trustee or investment manager of various pension and trust accounts Pyramis Global Advisors LLC (PGALLC) and Pyramis Trust Company (PTC).

SHARES HELD NOMINEE MANAGEMENT COMPANY 170,777 BANK OF NEW YORK FMRCO 51,000 BROWN BROTHERS HARRIMAN AND CO FMR 15,208,757 BROWN BROTHERS HARRIMAN AND CO FMRCO 22,900 BROWN BROTHERS HARRIMAN AND CO PTC 54,586 CIBC MELLON TRUST FCL 1,590,900 JP MORGAN CHASE BANK FMR 3,577,080 JP MORGAN CHASE BANK FMRCO 20,400 JP MORGAN CHASE BANK FMTC 69,799 JPMORGAN CHASE BANK FMR 388,800 JPMORGAN CHASE BANK PTC 87,700 MELLON BANK N.A. FMRCO 86,343 MELLON BANK N.A. FMTC 203,400 MELLON BANK N.A. PTC 18,500 NORTHERN TRUST CO FMRCO 117,304 NORTHERN TRUST CO FMTC 243,754 STATE STREET BANK AND TR CO FICL 18,018 STATE STREET BANK AND TR CO FMR 1,292,603 STATE STREET BANK AND TR CO FMRCO 335,584 STATE STREET BANK AND TR CO FMTC 310,951 STATE STREET BANK AND TR CO PTC 146,321 CIBC MELLON TRUST (C) FCL 159,000 ROYAL TRUST-TORONTO FCL 1,405,800 CITIBANK NA (C) FMR 28,800 MELLON BANK NA (C) PTC 2,309,901 NORTHERN TRUST CO (C) FMR 29,200 BANK OF NEW YORK MELLON PTC 66,200 NATIONAL BANK TRUST (C) FCL 32,300 ROYAL TRUST- TORONTO (C) FCL 31,407 ROYAL BANK OF CANADA © PTC 50,440 US BANK NA (C) PTC 1,111 N/A N/A Proxy Voting:10. Name of the proxy holder: FMR LLC

11. Number of voting rights proxy holder will acquire: 319,635

12. Date on which proxy holder will acquire voting rights: 14 April 2011

13. Additional information: Notification using the total voting rights figures of 562,241,550 14. Contact name: Philip Alexander 15. Contact telephone [email protected] - 01737 834624 number:

Contact at Shire plc: Tony Guthrie, Deputy Company Secretary, +44 1256 894746

For further information please contact:

Investor Relations Eric Rojas +1 781 482 0999 Notes to editors SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

vendor

Related Shares:

Shire
FTSE 100 Latest
Value8,774.65
Change-17.15